Skip to Main Content

Paper Details

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Ann Oncol
23
2020
Author NameAffiliation
Matti AnnalaUniversity of British Columbia, Tampere University
Sinja TaavitsainenTampere University
Martin E GleaveUniversity of British Columbia
Alexander W WyattUniversity of British Columbia
Kim N ChiUniversity of British Columbia
  • 1 - 5

Datasets

Release 1.2